223 related articles for article (PubMed ID: 25262803)
1. Tankyrase inhibitors as therapeutic targets for cancer.
Kamal A; Riyaz S; Srivastava AK; Rahim A
Curr Top Med Chem; 2014; 14(17):1967-76. PubMed ID: 25262803
[TBL] [Abstract][Full Text] [Related]
2. Tankyrases as drug targets.
Lehtiö L; Chi NW; Krauss S
FEBS J; 2013 Aug; 280(15):3576-93. PubMed ID: 23648170
[TBL] [Abstract][Full Text] [Related]
3. Insights of tankyrases: A novel target for drug discovery.
Damale MG; Pathan SK; Shinde DB; Patil RH; Arote RB; Sangshetti JN
Eur J Med Chem; 2020 Dec; 207():112712. PubMed ID: 32877803
[TBL] [Abstract][Full Text] [Related]
4. Regulation of Wnt/β-catenin signalling by tankyrase-dependent poly(ADP-ribosyl)ation and scaffolding.
Mariotti L; Pollock K; Guettler S
Br J Pharmacol; 2017 Dec; 174(24):4611-4636. PubMed ID: 28910490
[TBL] [Abstract][Full Text] [Related]
5. Discovery of potent and selective nonplanar tankyrase inhibiting nicotinamide mimics.
Nkizinkiko Y; Suneel Kumar BVS; Jeankumar VU; Haikarainen T; Koivunen J; Madhuri C; Yogeeswari P; Venkannagari H; Obaji E; Pihlajaniemi T; Sriram D; Lehtiö L
Bioorg Med Chem; 2015 Aug; 23(15):4139-4149. PubMed ID: 26183543
[TBL] [Abstract][Full Text] [Related]
6. The telomeric PARP, tankyrases, as targets for cancer therapy.
Seimiya H
Br J Cancer; 2006 Feb; 94(3):341-5. PubMed ID: 16421589
[TBL] [Abstract][Full Text] [Related]
7. Development of novel dual binders as potent, selective, and orally bioavailable tankyrase inhibitors.
Hua Z; Bregman H; Buchanan JL; Chakka N; Guzman-Perez A; Gunaydin H; Huang X; Gu Y; Berry V; Liu J; Teffera Y; Huang L; Egge B; Emkey R; Mullady EL; Schneider S; Andrews PS; Acquaviva L; Dovey J; Mishra A; Newcomb J; Saffran D; Serafino R; Strathdee CA; Turci SM; Stanton M; Wilson C; Dimauro EF
J Med Chem; 2013 Dec; 56(24):10003-15. PubMed ID: 24294969
[TBL] [Abstract][Full Text] [Related]
8. Tankyrase-targeted therapeutics: expanding opportunities in the PARP family.
Riffell JL; Lord CJ; Ashworth A
Nat Rev Drug Discov; 2012 Dec; 11(12):923-36. PubMed ID: 23197039
[TBL] [Abstract][Full Text] [Related]
9. Tankyrases: structure, function and therapeutic implications in cancer.
Haikarainen T; Krauss S; Lehtio L
Curr Pharm Des; 2014; 20(41):6472-88. PubMed ID: 24975604
[TBL] [Abstract][Full Text] [Related]
10. NuMA is a major acceptor of poly(ADP-ribosyl)ation by tankyrase 1 in mitosis.
Chang W; Dynek JN; Smith S
Biochem J; 2005 Oct; 391(Pt 2):177-84. PubMed ID: 16076287
[TBL] [Abstract][Full Text] [Related]
11. Tankyrase 1 as a target for telomere-directed molecular cancer therapeutics.
Seimiya H; Muramatsu Y; Ohishi T; Tsuruo T
Cancer Cell; 2005 Jan; 7(1):25-37. PubMed ID: 15652747
[TBL] [Abstract][Full Text] [Related]
12. Tankyrase as a Novel Molecular Target in Cancer and Fibrotic Diseases.
Lakshmi TV; Bale S; Khurana A; Godugu C
Curr Drug Targets; 2017; 18(10):1214-1224. PubMed ID: 27425647
[TBL] [Abstract][Full Text] [Related]
13. Zoning in on Tankyrases: A Brief Review on the Past, Present and Prospective Studies.
Peters XQ; Malinga TH; Agoni C; Olotu FA; Soliman MES
Anticancer Agents Med Chem; 2019; 19(16):1920-1934. PubMed ID: 31648650
[TBL] [Abstract][Full Text] [Related]
14. Regulation of tankyrase activity by a catalytic domain dimer interface.
Fan C; Yarravarapu N; Chen H; Kulak O; Dasari P; Herbert J; Yamaguchi K; Lum L; Zhang X
Biochem Biophys Res Commun; 2018 Sep; 503(3):1780-1785. PubMed ID: 30055800
[TBL] [Abstract][Full Text] [Related]
15. Structural basis of selective inhibition of human tankyrases.
Narwal M; Venkannagari H; Lehtiö L
J Med Chem; 2012 Feb; 55(3):1360-7. PubMed ID: 22233320
[TBL] [Abstract][Full Text] [Related]
16. Functional characterization of the poly(ADP-ribose) polymerase activity of tankyrase 1, a potential regulator of telomere length.
Rippmann JF; Damm K; Schnapp A
J Mol Biol; 2002 Oct; 323(2):217-24. PubMed ID: 12381316
[TBL] [Abstract][Full Text] [Related]
17. Targeting Wnt-driven cancers: Discovery of novel tankyrase inhibitors.
Ferri M; Liscio P; Carotti A; Asciutti S; Sardella R; Macchiarulo A; Camaioni E
Eur J Med Chem; 2017 Dec; 142():506-522. PubMed ID: 29107427
[TBL] [Abstract][Full Text] [Related]
18. Tankyrase-1 overexpression reduces genotoxin-induced cell death by inhibiting PARP1.
Yeh TY; Sbodio JI; Nguyen MT; Meyer TN; Lee RM; Chi NW
Mol Cell Biochem; 2005 Aug; 276(1-2):183-92. PubMed ID: 16132700
[TBL] [Abstract][Full Text] [Related]
19. Tankyrase is necessary for canonical Wnt signaling during kidney development.
Karner CM; Merkel CE; Dodge M; Ma Z; Lu J; Chen C; Lum L; Carroll TJ
Dev Dyn; 2010 Jul; 239(7):2014-23. PubMed ID: 20549720
[TBL] [Abstract][Full Text] [Related]
20. Tankyrase (PARP5) Inhibition Induces Bone Loss through Accumulation of Its Substrate SH3BP2.
Mukai T; Fujita S; Morita Y
Cells; 2019 Feb; 8(2):. PubMed ID: 30813388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]